M Tiikkainen, AM Häkkinen, E Korsheninnikova … - Diabetes, 2004 - Am Diabetes Assoc Both rosiglitazone and metformin increase hepatic insulin sensitivity, but their
mechanism of action has not been compared in humans. The objective of this study
was to compare the effects of rosiglitazone and metformin treatment on ... Cited by 276 - Related articles - BL Direct - All 6 versions
- ►infodiabetes.it [PDF] PD Home, SJ Pocock, H Beck-Nielsen, R … - Diabetologia, 2005 - Springer Page 1. Diabetologia (2005) 48: 1726–1735 DOI 10.1007/s00125-005-1869-1 ARTICLE
PD Home . SJ Pocock . H. Beck-Nielsen . R. Gomis . M. Hanefeld . H. Dargie . ... Cited by 147 - Related articles - BL Direct - All 5 versions
KA Virtanen, K Hällsten, R Parkkola, T … - Diabetes, 2003 - Am Diabetes Assoc We evaluated the effects of rosiglitazone (4 mg bid) and metformin (1 g bid)
monotherapy for 26 weeks on adipose tissue insulin-stimulated glucose uptake in
patients (n = 41) with type 2 diabetes. Before and after the treatment, ... Cited by 111 - Related articles - BL Direct - All 4 versions
- ►endojournals.org I Pavo, G Jermendy, TT Varkonyi, Z Kerenyi, … - Journal of Clinical Endocrinology & Metabolism, 2003 - Endocrine Soc Pioglitazone, a thiazolidinedione, improves glycemic control primarily by
increasing peripheral insulin sensitivity in patients with type 2 diabetes,
whereas metformin, a biguanide, exerts its effect primarily by decreasing ... Cited by 104 - Related articles - BL Direct - All 5 versions
GD Tan, BA Fielding, JM Currie, SM … - Diabetologia, 2005 - Springer Abstract Aims/hypothesis: We investigated the effects of rosiglitazone on NEFA
and triglyceride metabolism in type 2 diabetes. Methods: In a double-blind,
placebo-con- trolled, cross-over study of rosiglitazone in diet-treated ... Cited by 85 - Related articles - All 2 versions
- ►adisonline.com [PDF] M Rendell - Drugs, 2004 - ingentaconnect.com The sulphonylureas act by triggering insulin release from the pancreatic β
cell. Abstract A specific site on the adenosine triphosphate (ATP)-sensitive
potassium channels is occupied by sulphonylureas leading to closure of the ... Cited by 87 - Related articles - BL Direct - All 7 versions
A Natali, E Ferrannini - Diabetologia, 2006 - Springer Abstract Aims/hypothesis: Insulin resistance, which manifests itself as
endogenous glucose overproduction and reduced insulin-mediated glucose uptake,
is a core defect in type 2 diabetes. Metformin and the peroxisome ... Cited by 56 - Related articles - BL Direct - All 3 versions
Z Kerenyi, H Samer, R James, Y Yan, M … - Diabetes research and clinical practice, 2004 - Elsevier Aim: To compare the efficacy of combination therapy using rosiglitazone (8 mg
per day) and glibenclamide (7.5 mg per day) with upward titration of
glibenclamide as monotherapy (maximum dose=15 mg per day) in reducing HbA ... Cited by 50 - Related articles - All 8 versions
- ►endojournals.org C Bouche, S Serdy, CR Kahn, AB Goldfine - Endocrine reviews, 2004 - Endocrine Soc Type 2 diabetes is a complex disorder with diminished insulin secretion and
insulin action contributing to the hyperglycemia and wide range of metabolic
defects that underlie the disease. The contribution of glucose metabolic ... Cited by 51 - Related articles - BL Direct - All 6 versions
P Weissman, BJ Goldstein, J Rosenstock, B … - Current Medical Research and Opinion®, 2005 - informahealthcare.com P. Weissmana, BJ Goldsteinb, J. Rosenstockc, B. Waterhoused, AR Cobitzd, MJ
Wooddelld and LJ strowd ... Address for correspondence: Margaret Wooddell, PhD,
MPH, Metabolic/CV Medicine Development Center, GlaxoSmithKline ... Cited by 49 - Related articles - BL Direct - All 6 versions
